Volatile Stocks: Prosensa Holding (NASDAQ:RNA), 22nd Century Group Inc (NYSEMKT:XXII), Alnylam Pharmaceuticals (NASDAQ:ALNY), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)

Prosensa Holding NV (NASDAQ:RNA) was upgraded by stock analysts at KBC Securities from a “hold” rating to an “accumulate” rating in a report issued on Wednesday. The firm currently has a $11.00 price objective on the stock, up from their previous price objective of $7.00. KBC Securities’ target price would indicate a potential upside of 1.57% from the company’s current price. Prosensa Holding NV (NASDAQ:RNA) stock performance was 5.19% in last session and finished the day at $11.56. Traded volume was 779,032.00million shares in the last session and the average volume of the stock remained 432.80K shares.

A Clarence firm has signed a deal with a Polish cigarette manufacturer to make its tobacco products for distribution in the European Union. 22nd Century Group Inc. (NYSEMKT:XXII) makes low-nicotine cigarettes for the commercial market and for government sources for smoking cessation. 22nd Century Group Inc (NYSEMKT:XXII) rose 10.83 percent to $3.48 Monday on volume of 1.08million shares. The intra-day range of the stock was $3.13 to $3.54. 22nd Century Group Inc (NYSEMKT:XXII) has a market capitalization of $204.15million.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s stock on June 09, 2014 reported a increase of 7.53% to the closing price of $65.96. Its fifty two weeks range is $27.98 -$112.57. The total market capitalization recorded $4.98billion. The overall volume in the last trading session was 1.18million shares. In its share capital, ALNY has 75.55million outstanding shares.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on May 31 announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. On Monday, shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) advanced 7.84% to close the day at $1.10. Company return on investment (ROI) is -116.60%. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) quarterly revenue growth is -43.01%.

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) surged 7.69% after presenting encouraging data on its oncology candidate Ad-RTS-IL-12 at the annual meeting of the American Society of Gene and Cell Therapy (:ASGCT). ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was 1.49% in last session and finished the day at $4.08. Traded volume was 2.16million shares in the last session and the average volume of the stock remained 1.16million shares. The beta of the stock remained 2.00. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) insider ownership is 1.80%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone